Comment on do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.
作者信息
Huang Fang
机构信息
Department of Urology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
World J Urol. 2025 Aug 13;43(1):490. doi: 10.1007/s00345-025-05875-z.
PMID:40801959
Abstract
摘要
Zotero 插件